Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis.

Abstract

Risankizumab (Skyrizi^®, Abbvie, North Chicago, IL, USA) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting the p19 subunit of IL-23, thereby inhibiting IL-23-dependent releasing of proinflammatory cytokines in plaque psoriasis. Risankizumab is licensed is most countries for the treatment of patients with moderate-to-severe plaque psoriasis, and in Japan for generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis. Risankizumab showed higher efficacy and favorable safety profiles in patients with moderate-to-severe plaque psoriasis, compared with adalimumab, secukinumab and ustekinumab in several randomized controlled phase 3 pivotal studies and among real-life data in large retrospective studies. Furthermore, its high efficacy even in patients with prior biologic failure, better drug survival, less need for biologic switch and longer drug-free remission durations have also been shown in real-life settings and in long-term follow-up. In addition, reports of both reduced dosing and increased (bolus) dosing exist which increase our ability to use risankizumab more flexibly in an era of personalized medicine. Also, the use of risankizumab in several special population, such as elderly, Asian people, erythrodermic psoriasis, patients with high induction doses, pregnancy and human immunodeficiency virus group are discussed.